Table 2.
Treatment characteristics
| Every-3-weeks platinum | Weekly platinum | P-value | Every-3-weeks cisplatinum | Weekly carboplatinum | P-value | |
|---|---|---|---|---|---|---|
| (N = 144) | (N = 68) | (N = 138) | (N = 52) | |||
| RT timing | .05 | .18 | ||||
| Post-operative | 44 (30.6%) | 30 (44.1%) | 44 (31.9%) | 22 (42.3%) | ||
| Definitive | 100 (69.4%) | 38 (55.9%) | 94 (68.1%) | 30 (57.7%) | ||
| Induction chemotherapy | .60 | .59 | ||||
| Yes | 41 (28.5%) | 17 (25.0%) | 37 (26.8%) | 16 (30.8%) | ||
| No | 103 (71.5%) | 51 (75.0%) | 101 (73.2%) | 36 (69.2%) | ||
| Post-radiation lymph node dissection | .42 | .47 | ||||
| Yes | 19 (13.2%) | 5 (7.4%) | 18 (13.0%) | 4 (7.7%) | ||
| No | 81 (56.3%) | 33 (48.5%) | 76 (55.1%) | 26 (50.0%) | ||
| Not stated | 44 (30.6%) | 30 (44.1%) | 44 (31.9%) | 22 (42.3%) | ||
| RT technique | .57 | 0.68 | ||||
| 3D-conformal | 25 (17.4%) | 14 (20.6%) | 23 (16.7%) | 10 (19.2%) | ||
| IMRT | 119 (82.6%) | 54 (79.4%) | 115 (83.3%) | 42 (80.8%) | ||
| Type of chemotherapy | <.001 | <.001 | ||||
| Cisplatin | 138 (95.8%)a | 16 (23.5%) | 138 (100.0%) | 0 (0.0%) | ||
| Carboplatin | 9 (6.3%) | 52 (76.5%) | 0 (0.0%) | 52 (100.0%) | ||
| Alterations in RT course | .83 | .90 | ||||
| None | 82 (56.9%) | 40 (58.8%) | 78 (56.5%) | 31 (59.6%) | ||
| Delay | 43 (29.9%) | 21 (30.9%) | 41 (29.7%) | 15 (28.9%) | ||
| Truncations | 19 (13.2%) | 7 (10.3%) | 19 (13.8%) | 6 (11.5%) | ||
| Chemotherapy dose modification | .44 | .55 | ||||
| Yes | 76 (52.8%) | 32 (47.1%) | 73 (52.9%) | 25 (48.1%) | ||
| No | 68 (47.2%) | 36 (52.9%) | 65 (47.1%) | 27 (51.9%) |
RT radiotherapy, IMRT intensity modulated radiotherapy
aThree patients were treated with CDDP and switched to carboplatin. All were treated according to an every-3-weeks regimen